J Cell Mol Med. 2026 Jun;30(11):e71233. doi: 10.1111/jcmm.71233.
ABSTRACT
Cardiovascular diseases (CVD) remain the leading global cause of morbidity and mortality, driven in part by dysregulated redox homeostasis and chronic inflammation. Superoxide dismutase (SOD), a key enzymatic defence against reactive oxygen species (ROS), plays a central role in maintaining cardiovascular integrity through regulation of oxidative stress across cytosolic (SOD1), mitochondrial (SOD2) and extracellular (SOD3) compartments. Impairment of SOD function contributes directly to endothelial dysfunction, myocardial injury and vascular remodelling. Curcumin (Cur), a pleiotropic polyphenol derived from Curcuma longa, has emerged as a potent modulator of SOD activity and expression. Evidence from preclinical models consistently demonstrates that Cur enhances SOD-dependent antioxidant defences, thereby attenuating oxidative damage, inflammation, apoptosis and fibrosis across multiple CVD contexts, including myocardial infarction, cardiomyopathy, hypertension and diabetic complications. While Cur also influences additional signalling pathways, such as NF-κB, PI3K/AKT and Nrf2, these effects are increasingly understood to converge on SOD-mediated redox regulation. Recent advances in nanodelivery systems have further improved Cur bioavailability and its capacity to modulate SOD activity in vivo. However, despite robust preclinical evidence, clinical validation remains limited. This review synthesizes current mechanistic and translational evidence, positioning SOD as the central mediator of Cur's cardioprotective effects and highlights key gaps in clinical translation.
PMID:42252558 | DOI:10.1111/jcmm.71233